Please ensure Javascript is enabled for purposes of website accessibility

Here's What Caused Tandem Diabetes Stock to Gain a Jaw-Dropping 1,509% in 2018

By Todd Campbell - Updated Apr 15, 2019 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This insulin pump maker launched a revolutionary new treatment option for type 1 patients.

What happened

After the small-cap insulin pump maker won Food and Drug Administration approval for a new automated insulin-delivery solution last June, Tandem Diabetes Care (TNDM 4.43%) saw its shares skyrocket 1,509% in 2018, according to S&P Global Market Intelligence.

So what

Increasingly, type 1 diabetics who require frequent insulin injections to manage their disease are embracing technology, including Tandem's insulin pumps, that are less burdensome and help them control their disease better.

A woman draws a rocket on an ascending price chart.

Image source: Getty Images.

In the past, it's been tough for Tandem Diabetes to capture market share because of stiff competition from larger rivals, including Medtronic (MDT 1.82%) and Insulet (PODD 3.91%). However, it got a leg up on those competitors last summer, when the FDA approved a solution combining Tandem's pump and Basal-IQ algorithm, which uses data to predict dangerous insulin highs and lows, with a continuous glucose monitor made by DexCom (DXCM 4.16%).

Following the launch of this system in August, Tandem Diabetes shipped 8,434 pumps in the third quarter, up 118% year over year, and its revenue climbed 71.5% to $46.3 million because of robust demand. The third-quarter performance has management thinking it can break even on adjusted EBITDA for the first time in Q4 2018, which may mean it can take the leap to bottom-line profitability soon. 

Now what

Tandem Diabetes' market share is roughly 12%, and that means it has plenty of runway to grow revenue in 2019. It also doesn't hurt that one competitor, Johnson & Johnson's (JNJ 1.13%) Animas, exited the industry in late 2017, creating more opportunities for Tandem Diabetes to win converts. 

The path forward, however, might get bumpier in 2019. The rally in its share price last year puts its market cap over $2.2 billion, and competitors, including Insulet, could launch their own automated solutions in the next year or two, crimping demand. That suggests investors will want to keep close tabs on rivals and Tandem Diabetes' growth rates to make sure customers don't abandon it. 

Check out the latest Tandem Diabetes earnings call transcript.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tandem Diabetes Care Stock Quote
Tandem Diabetes Care
$61.81 (4.43%) $2.62
Johnson & Johnson Stock Quote
Johnson & Johnson
$179.52 (1.13%) $2.01
Medtronic plc Stock Quote
Medtronic plc
$91.38 (1.82%) $1.63
DexCom, Inc. Stock Quote
DexCom, Inc.
$77.63 (4.16%) $3.10
Insulet Corporation Stock Quote
Insulet Corporation
$226.46 (3.91%) $8.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/03/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.